ѻý

<ѻý class="page-title">Meeting Coverage

CMSC

<ѻý class="page-description">Consortium of Multiple Sclerosis Centers
Patient-Reported Outcomes Similar With Extended Natalizumab Dosing Interval

NOVA trial looks at 6-week dosing to reduce PML risk

CMSC over a photo of the Gaylord National Resort & Convention Center in Maryland
<ѻý class="section_title">Latest CMSC Meeting Coverage
High Density of MS Patients in Wisconsin -- But Why?

Health records show prevalence may be three times the norm in some areas

June 7, 2022
Plasma NfL Linked With Cognitive Processing Speed in Relapsing MS

Post hoc analysis of trial data shows inverse relationship

June 5, 2022
Quit MS Drugs or Keep Going?

DISCOMS trial looks at whether MS patients should stop treatment as they age

June 5, 2022
Women With MS Use Social Media to Discuss Family Planning

Posts offer insight into risks, experiences during pregnancy

June 4, 2022
Worse COVID-19 Outcomes for Disabled MS Patients

But monoclonal antibodies offer hope for high-risk people, registry data show

November 2, 2021
MS Treatment: Early Aggressive or Escalation Therapy?

Clinical trial, observational data may not be enough to decide best strategy

November 1, 2021
New MS Drug Does Not Appear to Increase COVID Severity

Most COVID cases were mild or moderate in patients treated with ofatumumab

October 29, 2021
Cannabis Use Common Among People With MS

Most don't ask for medical guidance, survey shows

October 28, 2021
Some Multiple Sclerosis Agents May be Safe During Pregnancy

Stopping treatment may put MS patients at unnecessary risk

June 5, 2018
Still No Clarity on Role of Vitamin D in MS Relapse

But findings do help estimate needed sample size for a future prospective study

June 4, 2018
MRI Improvements in MS with Switch from IFN to Ocrelizumab

Rapid and robust reduction in activity

June 4, 2018
A Good Guffaw Could Help MS Patients Cope

But pilot study of laughter therapy saw substantial dropout rate

June 4, 2018
When Is the Ideal Time for Some MS Patients to Start DMT?

Unclear benefits with disease-modifying therapies in older patients, asymptomatic patients

June 3, 2018
Twice-a-Week IFN Dose an Option in Breakthrough MS

Nearly two decades of data showed good outcomes

June 2, 2018